Copyright
©The Author(s) 2025.
World J Gastrointest Surg. Jan 27, 2025; 17(1): 101793
Published online Jan 27, 2025. doi: 10.4240/wjgs.v17.i1.101793
Published online Jan 27, 2025. doi: 10.4240/wjgs.v17.i1.101793
Table 1 General clinicopathologic characteristics, n (%)
| Variables | All patients (n = 107) | Propensity-matched patients (n = 94) | ||||||
| Total (n = 107) | ICG (n = 47) | Non-ICG (n = 60) | P value | Total (n = 94) | ICG (n = 47) | Non-ICG (n = 47) | P value | |
| Sex | 0.235 | 0.789 | ||||||
| Male | 83 (77.6) | 39 (83.0) | 44 (73.3) | 77 (81.9) | 39 (83.0) | 38 (80.9) | ||
| Female | 24 (22.4) | 8 (17.0) | 16 (26.7) | 17 (18.1) | 8 (17.0) | 9 (19.1) | ||
| Age, years | 58.4 (11.1) | 55.2 (12.2) | 61.0 (9.5) | 0.007 | 57.5 (11.1) | 55.2 (12.2) | 59.7 (9.4) | 0.059 |
| Hepatitis serology | 0.045 | 0.313 | ||||||
| None | 28 (26.2) | 8 (17.0) | 20 (33.3) | 20 (21.3) | 8 (17.0) | 12 (25.5) | ||
| HBV | 79 (73.8) | 39 (83.0) | 40 (66.7) | 74 (78.7) | 39 (83.0) | 35 (74.5) | ||
| PRE-OP Alb, g/L | 43.0 (3.7) | 43.0 (3.5) | 43.0 (3.9) | 0.959 | 43.0 (3.7) | 43.0 (3.5) | 42.9 (3.9) | 0.934 |
| PRE-OP TBil, μmol/L | 11.6 (6.5) | 12.2 (7.7) | 11.1 (5.4) | 0.401 | 11.9 (6.8) | 12.2 (7.7) | 11.6 (5.7) | 0.650 |
| PRE-OP ALT, U/L | 26.3 (14.9) | 27.6 (17.5) | 25.3 (12.5) | 0.437 | 26.3 (15.4) | 27.6 (17.5) | 25.1 (12.9) | 0.443 |
| PRE-OP AST, U/L | 24.7 (8.3) | 23.4 (6.6) | 25.7 (9.3) | 0.455 | 23.7 (7.0) | 23.4 (6.6) | 24.0 (7.5) | 0.715 |
| Tumor location | 0.2 | 0.272 | ||||||
| caudal lobe | 2 (1.9) | 1 (2.1) | 1 (1.7) | 2 (2.1) | 1 (2.1) | 1 (2.1) | ||
| Left lateral lobe | 8 (7.5) | 6 (12.8) | 2 (3.3) | 8 (8.5) | 6 (12.8) | 2 (4.3) | ||
| Left medial lobe | 15 (14.0) | 9 (19.1) | 6 (10.0) | 14 (14.9) | 9 (19.1) | 5 (10.6) | ||
| Right anterior lobe | 42 (39.3) | 16 (34.0) | 26 (43.3) | 41 (43.6) | 16 (34.0) | 25 (53.2) | ||
| Right posterior lobe | 40 (37.4) | 15 (31.9) | 25 (41.7) | 29 (30.9) | 15 (31.9) | 14 (29.8) | ||
| Tumor size, cm | 3.1 (1.6) | 2.9 (1.7) | 3.3 (1.5) | 0.256 | 3.1 (1.6) | 2.9 (1.7) | 3.3 (1.6) | 0.234 |
| Tumor amount | 0.282 | 0.212 | ||||||
| Single | 97 (90.7) | 41 (87.2) | 56 (93.3) | 85 (90.4) | 41 (87.2) | 44 (93.6) | ||
| Multiple | 10 (9.3) | 6 (12.8) | 4 (6.7) | 9 (9.6) | 6 (12.8) | 3 (6.4) | ||
| Histological grading | 0.341 | 0.460 | ||||||
| I-II | 96 (89.7) | 44 (93.6) | 52 (86.7) | 86 (91.5) | 44 (93.6) | 42 (89.4) | ||
| III | 11 (10.3) | 3 (6.4) | 8 (13.3) | 8 (8.5) | 3 (6.4) | 5 (10.6) | ||
| Degree of hepatic fibrosis | 0.426 | 0.408 | ||||||
| 0-III | 57 (53.3) | 23 (48.9) | 34 (56.7) | 50 (53.2) | 23 (48.9) | 27 (57.4) | ||
| IV | 50 (46.7) | 24 (51.1) | 26 (43.3) | 44 (46.8) | 24 (51.1) | 20 (42.6) | ||
| MVI | 0.146 | 0.298 | ||||||
| M0 | 63 (58.9) | 24 (51.1) | 39 (65.0) | 53 (56.4) | 24 (51.1) | 29 (61.7) | ||
| M1-2 | 44 (41.1) | 23 (48.9) | 21 (35.0) | 41 (43.6) | 23 (48.9) | 18 (38.3) | ||
Table 2 Specific intra-operative outcomes, n (%)
| Variables | Total (n = 94) | ICG (n = 47) | Non-ICG (n = 47) | P value |
| Blood loss, mL | 124.4 (111.8) | 85.5 (59.6) | 163.2 (136.5) | 0.001 |
| Surgery time, minute | 152.6 (62.4) | 128.2 (43.6) | 177.0 (68.9) | < 0.001 |
| HIO times | 0.005 | |||
| 0 | 5 (5.3) | 4 (8.5) | 1 (2.1) | |
| 1 | 30 (31.9) | 20 (42.6) | 10 (21.3) | |
| 2 | 40 (42.6) | 20 (42.6) | 20 (42.6) | |
| 3 | 17 (18.1) | 2 (4.3) | 15 (31.9) | |
| 4 | 2 (2.1) | 1 (2.1) | 1 (2.1) | |
| Total HIO time, minute | 28.9 (13.6) | 25.1 (13.2) | 32.7 (13.2) | 0.007 |
| Margin, mm | 8.6 (6.9) | 8.8 (6.4) | 8.3 (7.5) | 0.724 |
Table 3 Specific post-operative outcomes, n (%)
| Variables | Total (n = 94) | ICG (n = 47) | Non-ICG (n = 47) | P value |
| POST-OP PT1, second | 13.9 (1.1) | 13.9 (0.9) | 13.9 (1.2) | 0.829 |
| POST-OP TBil1, μmol/L | 26.4 (13.5) | 27.5 (14.2) | 25.2 (12.7) | 0.418 |
| POST-OP ALT1, U/L | 272.1 (236.1) | 247.5 (159.0) | 296.7 (290.3) | 0.311 |
| POST-OP AST1, U/L | 238.0 (255.1) | 200.0 (129.7) | 275.9 (334.4) | 0.151 |
| POST-OP hospitalization, days | 7.1 (2.6) | 6.5 (1.2) | 7.6 (3.4) | 0.030 |
| Clavien-Dindo complications | 0.399 | |||
| None or grade I | 88 (93.6) | 45 (95.7) | 43 (91.5) | |
| Grade II | 6 (6.4) | 2 (4.3) | 4 (8.5) | |
| POST-OP TACE | 0.674 | |||
| Negative | 56 (59.6) | 29 (61.7) | 27 (57.4) | |
| Positive | 38 (40.4) | 18 (38.3) | 20 (42.6) | |
| Recurrence | 1.000 | |||
| Negative | 88 (93.6) | 44 (93.6) | 44 (93.6) | |
| Positive | 6 (6.4) | 3 (6.4) | 3 (6.4) |
Table 4 Trends of inflammation-related markers during the perioperative period
| Variables | Total (n = 94) | ICG (n = 47) | Non-ICG (n = 47) | P value |
| PRE-OP inflammation-related markers | ||||
| CRP | 1.8 (3.5) | 1.8 (4.4) | 1.7 (2.2) | 0.918 |
| NLR | 1.9 (0.8) | 1.9 (0.9) | 1.9 (0.8) | 0.990 |
| PLR | 98.7 (35.5) | 95.5 (33.2) | 101.8 (37.8) | 0.395 |
| LMR | 4.0 (1.5) | 4.0 (1.3) | 3.9 (1.8) | 0.701 |
| SII | 345.2 (200.0) | 332.6 (196.9) | 357.8 (204.4) | 0.544 |
| POST-OP inflammation-related markers | ||||
| CRP1 | 70.5 (49.8) | 61.1 (49.4) | 80.0 (49.0) | 0.066 |
| D1 NLR | 8.5 (4.7) | 8.2 (4.1) | 8.8 (5.3) | 0.536 |
| D1 PLR | 148.2 (67.8) | 134.3 (53.6) | 162.1 (77.6) | 0.046 |
| D1 LMR | 1.6 (0.8) | 1.5 (0.8) | 1.6 (0.7) | 0.619 |
| D1 SII | 1306.9 (813.9) | 1197.3 (644.4) | 1416.5 (948.4) | 0.193 |
| D3 NLR | 5.4 (4.1) | 4.5 (2.9) | 6.3 (4.9) | 0.033 |
| D3 PLR | 107.7 (61.0) | 102.0 (40.0) | 113.3 (76.6) | 0.373 |
| D3 LMR | 2.4 (3.9) | 2.0 (0.8) | 2.9 (5.5) | 0.278 |
| D3 SII | 708.7 (569.3) | 601.3 (451.5) | 816.1 (654.0) | 0.067 |
- Citation: Wu WX, Huang MB, Wang MX, Chen LH, Hu B, Ding ZB. Laparoscopic hepatectomy using indocyanine green attenuates postoperative inflammatory response for hepatocellular carcinoma: A propensity score matching analysis. World J Gastrointest Surg 2025; 17(1): 101793
- URL: https://www.wjgnet.com/1948-9366/full/v17/i1/101793.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v17.i1.101793